Oslo University Hospital HF

The Department of Oncology at Oslo University Hospital HF is advancing research in blood‑related and lymphatic disorders, with a particular focus on cancer-associated cachexia and vascular malformation. Clinical studies aim to test novel therapies and improve patient outcomes.

• Evaluation of monoclonal antibody therapy
• Assessment of surgical and laser interventions for vascular lesions
• Long‑term safety monitoring
• Patient‑reported outcome measures

Ongoing trials evaluate the potential of visugromab to reduce wasting in cachexia and assess sirolimus for long‑term reduction of vascular lesion volume, reflecting the site’s commitment to innovative treatment strategies.

Research in this therapeutic area explores the metabolic and nutritional challenges associated with cancer, especially the severe weight loss seen in cancer-associated cachexia. The goal is to identify interventions that can preserve body composition and improve quality of life.

• Nutritional supplementation trials
• Metabolic biomarker identification
• Combination therapy with anti‑catabolic agents
• Health‑related quality of life studies

By integrating metabolic profiling with clinical endpoints, the investigators at Oslo University Hospital HF aim to establish new standards for managing cachexia and related metabolic disturbances.